Tekla Life Sciences Stock Statistic Functions Linear Regression
| HQL Stock | USD 16.75 0.45 2.76% |
| Symbol |
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Linear Regression model generates relationship between price series of Tekla Life Sciences and its peer or benchmark and helps predict Tekla Life future price from its past values.
Tekla Life Technical Analysis Modules
Most technical analysis of Tekla Life help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Tekla from various momentum indicators to cycle indicators. When you analyze Tekla charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Tekla Life Sciences Investors
The stock is still going through the normal trading activities.Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange. The profile for Tekla Life integrates fundamentals, price behavior, and sector exposure. Defensive traits reduce macro sensitivity. Tekla Life has market cap of 482.46 M, P/E of 2.84, ROE of 17.59%.
Methodology
Unless otherwise specified, financial data for Tekla Life Sciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tekla (USA Stocks:HQL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tekla Life Sciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Become your own money manager
Tracking Tekla Life inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | Baby Boomer Prospects Invested over 60 shares | |
 | ESG Investing Invested few shares | |
 | Investor Favorites Invested over 200 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Power Assets Invested over 200 shares | |
 | Artificial Intelligence Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Momentum Invested over 20 shares | |
More Resources for Tekla Stock Analysis
Reviewing Tekla Life Sciences commonly begins with financial statements and performance trends. Ratio context helps frame profitability, efficiency, and growth trends for Tekla Life Sciences Stock. Key reports that frame Tekla Life Sciences Stock are listed below:Tekla Life has market cap of 482.46 M, P/E of 2.84, operating margin of -3.47%. See Risk vs Return Analysis for portfolio-level analysis. This suggests a position in Tekla Life Sciences in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.Analysis related to Tekla Life should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Understanding Tekla Life Sciences includes distinguishing between market value and book value, where book value reflects Tekla accounting equity. Tekla Life's market capitalization is 482.46 M. A P/B ratio of 0.94 suggests Tekla Life trades near or below book value. Enterprise value stands at 482.38 M. Intrinsic value is an analytical estimate of Tekla Life's underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
The concept of value for Tekla Life differs from its quoted price, since each reflects a different lens. For Tekla Life, key inputs include a P/E ratio of 2.84, a P/B ratio of 0.94, a profit margin of 44.16%, ROE of 17.59%. The quoted price is simply the exchange level where supply meets demand.